Current State of Liver Transplantation for Cholangiocarcinoma: A Comprehensive Literature Review
Exp Clin Transplant. 2024 Mar;22(3):167-179. doi: 10.6002/ect.2023.0343.ABSTRACTCholangiocarcinoma is the second most common primary hepatic neoplasm, accounting for 10% to 20% of primary liver tumors and 3% of all gastrointestinal neoplasms. The 3 anatomic types (intrahepatic, perihilar, and distal) have distinct epidemiologies, etiopathogenesis, and clinical outcomes. Surgical resection remains the current standard of treatment, but outcomes remain poor. With the continued expansion of liver transplant programs, use of liver transplant for malignant indications has also increased, with reports of encouraging outcomes. Ho...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - May 2, 2024 Category: Transplant Surgery Authors: Junaid Mansoor Nigel Heaton Zartash Junaid Source Type: research
Approval of Mycophenolate Mofetil for Prophylaxis of Organ Rejection in Pediatric Recipients of Heart or Liver Transplants: A Regulatory Perspective
Clin Pharmacol Ther. 2024 May 2. doi: 10.1002/cpt.3288. Online ahead of print.ABSTRACTOn June 6, 2022, the FDA expanded the indications for mycophenolate mofetil (MMF) to include the prophylaxis of organ rejection in combination with other immunosuppressants in pediatric recipients of allogeneic heart or liver transplants aged 3 months and older. The approved oral dosing regimen for these patients was a starting dose of 600 mg/m2 with titration up to a maximum of 900 mg/m2 twice daily. Data to support efficacy in pediatric patients were derived from established pharmacokinetic (PK) relationships across approved populations...
Source: Clinical Pharmacology and Therapeutics - May 2, 2024 Category: Drugs & Pharmacology Authors: Amer Al-Khouja Nadia Chaudhri Ergun Velidedeoglu Ozlem Belen Youwei Bi Suresh Doddapaneni Jianmeng Chen Source Type: research
Succinylation of Park 7 Activates a Protective Metabolic Response to Acute Kidney Injury
In this study we show in vitro and in vivo that Park7 has a crucial role in protection from AKI, and upregulated peroxisome activity. These data in combination with published results of Park7's protective role in cardiovascular damage and chronic kidney disease lead us to hypothesize that succinylation of Park7 may ameliorate oxidative damage resulting from AKI and prevent disease progression. This novel mechanism provides a potential therapeutic mechanism that can be targeted.PMID:38695076 | DOI:10.1152/ajprenal.00062.2024 (Source: Am J Physiol Renal P...)
Source: Am J Physiol Renal P... - May 2, 2024 Category: Urology & Nephrology Authors: Katherine Pfister Victoria Young Brendon Frankel Anne Silva Barbosa Jordan Burton Joanna Bons Bob Zhang Takuto Chiba Rebecca Uhlean Eric Goetzman Birgit Schilling Sunder Sims-Lucas Source Type: research
Lower Opportunity ZIP Code Is Associated with Worse Outcomes after Listing in Pediatric Heart Transplantation
We describe association between COI and outcomes after listing for heart transplantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - May 2, 2024 Category: Transplant Surgery Authors: Heidi A. Kim, Andrew G. Yu, Nicole P. Kim, Mehreen S. Iqbal, Ryan Butts Source Type: research
Discovering the Limits of the Possible: Two Can Play That Game
The only way to discover the limits of the possible is to go beyond them into the impossible (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - May 2, 2024 Category: Transplant Surgery Authors: Yael Peled, Michelle M. Kittleson Source Type: research
External validation of population pharmacokinetic models of tacrolimus in Thai adult liver transplant recipients
ConclusionBayesian forecasting is more accurate and precise than other testing methods for predicting drug concentrations. However, none of the evaluated models provides satisfactory predictive performance for generalization to Thai liver transplant patients. This underscores the need for future research to develop population PK models tailored to the Thai population. Such efforts should consider the inclusion of nonlinear pharmacokinetics and region-specific factors, including genetic variability, to improve model accuracy and applicability. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - May 2, 2024 Category: Drugs & Pharmacology Source Type: research
Relative carcinogenicity of tacrolimus < em > vs < /em > mycophenolate after solid organ transplantation and its implications for liver transplant care
CONCLUSION: The contrasting carcinogenic risk profiles of tacrolimus and MPA demonstrated in previous experimental studies, and its application in solid organ transplantation, is yet to be confirmed in clinical studies. Thus, the optimal choice of immunosuppression drug to use as maintenance monotherapy in LT recipients is not supported by a strong evidence base and remains unclear.PMID:38689747 | PMC:PMC11056899 | DOI:10.4254/wjh.v16.i4.650 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Dorothy Liu Mark M Youssef Josephine A Grace Marie Sinclair Source Type: research
Sacubitril-valsartan vs ACE/ARB in pediatric heart failure: A retrospective cohort study
The first angiotensin receptor/neprilysin inhibitor on the market, sacubitril-valsartan, has shown marked improvements in death and hospitalization for heart failure among adults, and is now approved for use in pediatric heart failure. While the ongoing PANORAMA-HF trial is evaluating the effectiveness of sacubitril-valsartan for pediatric patients with a failing systemic left ventricle, the enrollment criteria do not include the majority of pediatric heart failure patients. Additional studies are needed. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - May 1, 2024 Category: Transplant Surgery Authors: Zachariah E. Hale, Laura Prichett, Simran Jandu, William Ravekes Tags: Original clinical science Source Type: research
Innovating to resolve the pressure-oxygenation-paradox created by VA-ECMO could improve outcomes for acute myocardial infarction and cardiogenic shock
VA-ECMO use is growing exponentially. Recent data shows no clinical benefit with routine use of VA-ECMO in acute myocardial infarction and shock, however clinical experience with ECMO is growing. Two key variables that may impact outcomes with ECMO in acute myocardial infarction and shock include it's effect on systemic pressure and oxygenation. We define the pressure-oxygenaton paradox of ECMO as a potential new avenue for therapeutic discovery. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - May 1, 2024 Category: Transplant Surgery Authors: Navin K. Kapur Tags: Perspective Source Type: research
Editorial Board
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - May 1, 2024 Category: Transplant Surgery Source Type: research
Information for Readers
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - May 1, 2024 Category: Transplant Surgery Source Type: research
Table of Contents
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - May 1, 2024 Category: Transplant Surgery Source Type: research
